Fulgent Genetics, Inc. - Common Stock (NQ:FLGT)

19.88 +0.27 (+1.38%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 21, 2026 Add to My Watchlist

Price and Volume

Volume	299,560
Open	19.52
Bid (Size)	14.02 (100)
Ask (Size)	20.00 (500)
Prev. Close	19.61
Today's Range	19.45 - 19.93
52wk Range	13.46 - 31.04
Shares Outstanding	29,926,846
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Fulgent to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026

July 09, 2026

From Fulgent Genetics, Inc.

Via Business Wire

Fulgent Presents Updated FID-007 Data at ASCO 2026

June 01, 2026

From Fulgent Genetics, Inc.

Via Business Wire

Performance

YTD	-22.3%	-22.3%
1 Month	+11.4%	+11.4%
3 Month	+24.7%	+24.7%
6 Month	-28.2%	-28.2%
1 Year	+12.0%	+12.0%

More News

Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm

May 22, 2026

From Lowey Dannenberg, P.C.

Via GlobeNewswire

Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting

May 21, 2026

From Fulgent Genetics, Inc.

Via Business Wire

Fulgent Genetics (NASDAQ:FLGT) Shares Dip Premarket After Q1 Earnings Miss Despite Revenue Beat ↗

May 01, 2026

Via Chartmill

Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm

May 08, 2026

From Lowey Dannenberg, P.C.

Via GlobeNewswire

Fulgent (FLGT) Q1 2026 Earnings Transcript ↗

May 01, 2026

Via The Motley Fool

Fulgent Reports First Quarter 2026 Financial Results

May 01, 2026

From Fulgent Genetics, Inc.

Via Business Wire

Fulgent Selected to Present Rapid Oral Abstract Within the Head and Neck Cancer Track Session at the 2026 ASCO Annual Meeting

April 22, 2026

From Fulgent Genetics, Inc.

Via Business Wire

Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm

April 17, 2026

From Lowey Dannenberg, P.C.

Via GlobeNewswire

Fulgent to Announce First Quarter 2026 Financial Results on Friday, May 1, 2026

April 16, 2026

From Fulgent Genetics, Inc.

Via Business Wire

FULGENT INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Fulgent Genetics, Inc. on Behalf of Fulgent Stockholders and Encourages Investors to Contact the Firm

April 01, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

FLGT INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Fulgent Genetics Inc.

March 25, 2026

From Kirby McInerney LLP

Via Business Wire

FLGT INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Fulgent Genetics Inc.

March 23, 2026

From Kirby McInerney LLP

Via GlobeNewswire

FLGT SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

March 19, 2026

From Kirby McInerney LLP

Via GlobeNewswire

FULGENT GENETICS INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

March 17, 2026

From Kirby McInerney LLP

Via Business Wire

Fulgent Genetics Completes Acquisition of Bako Diagnostics and StrataDx

March 17, 2026

From Fulgent Genetics, Inc.

Via Business Wire

Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm

March 16, 2026

From Lowey Dannenberg, P.C.

Via GlobeNewswire

Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm

March 12, 2026

From Lowey Dannenberg, P.C.

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT

March 10, 2026

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT

March 03, 2026

From Pomerantz LLP

Via GlobeNewswire

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗

February 27, 2026

Via Chartmill

Which stocks are moving on Friday? ↗

February 27, 2026

Via Chartmill

Gapping stocks in Friday's session ↗

February 27, 2026

Via Chartmill

Fulgent Genetics (FLGT) Earnings Transcript ↗

February 27, 2026

Via The Motley Fool

Frequently Asked Questions

Is Fulgent Genetics, Inc. - Common Stock publicly traded?

Yes, Fulgent Genetics, Inc. - Common Stock is publicly traded.

What exchange does Fulgent Genetics, Inc. - Common Stock trade on?

Fulgent Genetics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Fulgent Genetics, Inc. - Common Stock?

The ticker symbol for Fulgent Genetics, Inc. - Common Stock is FLGT on the Nasdaq Stock Market

What is the current price of Fulgent Genetics, Inc. - Common Stock?

The current price of Fulgent Genetics, Inc. - Common Stock is 19.88

When was Fulgent Genetics, Inc. - Common Stock last traded?

The last trade of Fulgent Genetics, Inc. - Common Stock was at 07/21/26 04:00 PM ET

What is the market capitalization of Fulgent Genetics, Inc. - Common Stock?

The market capitalization of Fulgent Genetics, Inc. - Common Stock is 594.95M

How many shares of Fulgent Genetics, Inc. - Common Stock are outstanding?

Fulgent Genetics, Inc. - Common Stock has 595M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.